$0.36
▲ +2.8% Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
CytoSorbents Announces Reverse Stock Split
CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor
Overview
52-week range
$0.30
$1.04
8% of range
Avg surprise (last 3)
+6.7%
Avg reaction (last 2)
-4.8%
0% positive
Latest IV / EM
7448%
EM ±1204.6% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.07 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.08 | $-0.06 | -33.3% | -33.3% | -2.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.05 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.05 | $-0.07 | +28.6% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.06 | $-0.08 | +25.0% | — | -7.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.05 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.08 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.11 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $9M | — | $9M | $10M | $9M | — | $9M |
| Cost of revenue | $3M | $3M | — | $3M | $3M | $3M | — | $3M |
| Gross profit | $7M | $6M | — | $7M | $7M | $6M | — | $5M |
| Operating income | $-3M | $-3M | — | $-3M | $-4M | $-4M | — | $-5M |
| Net income | $-4M | $-5M | — | $-3M | $2M | $-1M | — | $-3M |
| EPS (diluted) | $-0.07 | $-0.08 | — | $-0.05 | $0.03 | $-0.02 | — | $-0.05 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4M | $5M | $6M | $8M | $10M | $12M | $3M | $6M |
| Inventory | $4M | $4M | $5M | $4M | $4M | $3M | $3M | — |
| Total current assets | $16M | $18M | $21M | $21M | $23M | $25M | $22M | — |
| Total assets | $38M | $41M | $44M | $46M | $48M | $51M | $47M | — |
| Long-term debt | $3M | $10M | $17M | $15M | $14M | $14M | $14M | $14M |
| Total liabilities | $39M | $38M | $38M | $37M | $36M | $36M | $36M | — |
| Total equity | $-751,000 | $2M | $6M | $9M | $12M | $15M | $11M | $13M |